Literature DB >> 25340269

MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside.

Jan Bogaert1, Iacopo Olivotto.   

Abstract

Hypertrophic cardiomyopathy ( HCM hypertrophic cardiomyopathy ), the most common genetically transmitted cardiac disorder, has been the focus of extensive research over the past 50 years. HCM hypertrophic cardiomyopathy is a multifaceted disease with highly heterogeneous genetic background, phenotypic expression, clinical presentation, and long-term outcome. Though most patients have an indolent course with a life expectancy comparable to that of the general population, early diagnosis and accurate risk profiling are essential to identify the sizeable subset at increased risk of sudden cardiac death or disease progression and heart failure-related complications, requiring aggressive management options. Imaging has a central role in the diagnosis and prognostic assessment of HCM hypertrophic cardiomyopathy patients, as well as screening of potentially affected family members. In this context, magnetic resonance (MR) imaging has recently emerged as an ideal complement to transthoracic echocardiography. Its multiparametric approach, fusing spatial, contrast, and temporal resolution, provides the clinician with detailed characterization of the HCM hypertrophic cardiomyopathy phenotype and assessment of its functional consequences including causes and site of dynamic obstruction, presence and extent of myocardial perfusion abnormalities, and fibrosis. Moreover, MR is key in differentiating HCM hypertrophic cardiomyopathy from "phenocopies"-that is, hearts with similar morphology but profoundly different etiology, such as amyloid or Anderson-Fabry disease. Long term, the incremental information provided by MR is relevant to planning of septal reduction therapies, identification of the early stages of end-stage progression, and stratification of arrhythmic risk. The aim of this review is to depict the increasingly important role of MR imaging in relation to the complexity of HCM hypertrophic cardiomyopathy , highlighting its role in clinical decision making.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25340269     DOI: 10.1148/radiol.14131626

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  20 in total

1.  Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis.

Authors:  Gaetano Nucifora; Daniele Muser; Pasquale Gianfagna; Giorgio Morocutti; Alessandro Proclemer
Journal:  Int J Cardiovasc Imaging       Date:  2015-07-26       Impact factor: 2.357

Review 2.  Imaging of Left Ventricular Hypertrophy: a Practical Utility for Differential Diagnosis and Assessment of Disease Severity.

Authors:  Toru Kubo; Hiroaki Kitaoka
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

Review 3.  The Muscle-Bound Heart.

Authors:  Marwan M Refaat; Akl C Fahed; Sylvana Hassanieh; Mostafa Hotait; Mariam Arabi; Hadi Skouri; Jonathan G Seidman; Christine E Seidman; Fadi F Bitar; Georges Nemer
Journal:  Card Electrophysiol Clin       Date:  2016-03

4.  Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.

Authors:  Helga Castagnoli; Cecilia Ferrantini; Raffaele Coppini; Alessandro Passeri; Katia Baldini; Valentina Berti; Franco Cecchi; Iacopo Olivotto; Roberto Sciagrà
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-16       Impact factor: 9.236

5.  Cardiac MR enables diagnosis in 90% of patients with acute chest pain, elevated biomarkers and unobstructed coronary arteries.

Authors:  T Emrich; K Emrich; N Abegunewardene; K Oberholzer; C Dueber; T Muenzel; K-F Kreitner
Journal:  Br J Radiol       Date:  2015-03-18       Impact factor: 3.039

Review 6.  Cardiac Imaging in the Athlete: Shrinking the "Gray Zone".

Authors:  Mario R Caruso; Lohit Garg; Matthew W Martinez
Journal:  Curr Treat Options Cardiovasc Med       Date:  2020-02-03

Review 7.  Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease.

Authors:  Giovanni Quarta; Michael Papadakis; Paolo Di Donna; Niccolò Maurizi; Attilio Iacovoni; Antonello Gavazzi; Michele Senni; Iacopo Olivotto
Journal:  Nat Rev Cardiol       Date:  2016-11-10       Impact factor: 32.419

Review 8.  Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline.

Authors:  Ariane Fraiche; Andrew Wang
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

9.  Novel Phenotype-Genotype Correlations of Restrictive Cardiomyopathy With Myosin-Binding Protein C (MYBPC3) Gene Mutations Tested by Next-Generation Sequencing.

Authors:  Wei Wu; Chao-Xia Lu; Yi-Ning Wang; Fang Liu; Wei Chen; Yong-Tai Liu; Ye-Chen Han; Jian Cao; Shu-Yang Zhang; Xue Zhang
Journal:  J Am Heart Assoc       Date:  2015-07-10       Impact factor: 5.501

Review 10.  Status and potential clinical value of a transthoracic evaluation of the coronary arteries.

Authors:  Fabien Labombarda; Samuela Castelnuovo; Dionysis Goularas; Cesare R Sirtori
Journal:  Cardiovasc Ultrasound       Date:  2016-01-19       Impact factor: 2.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.